Skip to main content

Advertisement

SpringerLink
Log in

LunelleTM monthly injectable contraceptive

An effective, safe, and convenient new birth control option

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract 

LunelleTM, an injectable estrogen/progestin contraceptive, is administered on a monthly basis and is now available as the first monthly injectable in the United States. International and US clinical trials have established its safety and confirmed its contraceptive efficacy. Fertility returns rapidly after discontinuation of injections. Studies have noted a high level of patient satisfaction with Lunelle, suggesting that monthly injectable contraception will become a first-line contraceptive option in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Florida, 653-1 West 8th Street, Jacksonville, FL 32209 e-mail: andrew.kaunitz@jax.ufl.edu Tel.: 904-2443271, Fax: 904-2443124, , , , , , US

    A. M. Kaunitz

Authors
  1. A. M. Kaunitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received: 18 January 2001 / Accepted: 23 February 2001

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaunitz, A. LunelleTM monthly injectable contraceptive . Arch Gynecol Obstet 265, 119–123 (2001). https://doi.org/10.1007/s004040100174

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004040100174

Search

Navigation